OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SWTX, HZNP, BSX, PFE, THRX, and represent 19.05% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: BHVN (+$85M), PFE (+$67M), BMRN (+$61M), GBT (+$56M), ARGX (+$54M), ISRG (+$48M), THC (+$28M), HUM (+$28M), SIBN (+$19M), MRTX (+$17M).
- Started 11 new stock positions in IMCR, RARE, SGFY, Bridgebio Pharma, MIRM, BHVN, GBT, Vigil Neuroscience, ARGX, ALBO. Bridgebio Pharma.
- Reduced shares in these 10 stocks: , BMY (-$127M), , XBI (-$81M), , ZBH (-$72M), VRTX (-$67M), OSH (-$43M), BSX (-$42M), .
- Sold out of its positions in AADI, ADAG, APLT, AUGX, DRUG, CVRX, CBIO, IPSC, CRIS, CTKB.
- Orbimed Advisors was a net seller of stock by $-467M.
- Orbimed Advisors has $6.2B in assets under management (AUM), dropping by -20.78%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Companies in the Orbimed Advisors portfolio as of the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Springworks Therapeutics (SWTX) | 5.5 | $340M | 6.0M | 56.44 | ||
| Horizon Therapeutics Pub L SHS (HZNP) | 3.7 | $231M | -12% | 2.2M | 105.21 | |
| Boston Scientific Corporation (BSX) | 3.3 | $204M | -17% | 4.6M | 44.29 | |
| Pfizer (PFE) | 3.3 | $202M | +49% | 3.9M | 51.77 | |
| Theseus Pharmaceuticals (THRX) | 3.2 | $197M | 17M | 11.53 | ||
| Bristol Myers Squibb (BMY) | 3.1 | $190M | -39% | 2.6M | 73.03 | |
| Humana (HUM) | 2.7 | $166M | +19% | 382k | 435.17 | |
| Intuitive Surgical Com New (ISRG) | 2.6 | $161M | +42% | 534k | 301.68 | |
| UnitedHealth (UNH) | 2.4 | $150M | +8% | 294k | 509.97 | |
| Adicet Bio (ACET) | 2.4 | $149M | 7.4M | 19.97 | ||
| Abbvie (ABBV) | 2.4 | $148M | -14% | 916k | 162.11 | |
| Pmv Pharmaceuticals (PMVP) | 2.3 | $143M | -6% | 6.9M | 20.82 | |
| Edgewise Therapeutics (EWTX) | 2.2 | $135M | 14M | 9.70 | ||
| Mirati Therapeutics (MRTX) | 2.2 | $134M | +14% | 1.6M | 82.22 | |
Setup an alertOrbiMed Advisors will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| BioMarin Pharmaceutical (BMRN) | 2.1 | $127M | +91% | 1.6M | 77.10 | |
| Edwards Lifesciences (EW) | 2.0 | $124M | -2% | 1.1M | 117.72 | |
| Stryker Corporation (SYK) | 2.0 | $122M | 457k | 267.35 | ||
| Arcutis Biotherapeutics (ARQT) | 1.9 | $117M | 6.1M | 19.26 | ||
| Iovance Biotherapeutics (IOVA) | 1.8 | $110M | +4% | 6.6M | 16.65 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.7 | $104M | -39% | 400k | 260.97 | |
| Seagen (SGEN) | 1.6 | $96M | 668k | 144.05 | ||
| Keros Therapeutics (KROS) | 1.5 | $91M | 1.7M | 54.38 | ||
| Guardant Health (GH) | 1.4 | $88M | +7% | 1.3M | 66.24 | |
| Biohaven Pharmaceutical Holding (BHVN) | 1.4 | $85M | NEW | 719k | 118.57 | |
| Tricida (TCDA) | 1.4 | $85M | 10M | 8.22 | ||
| Neurocrine Biosciences (NBIX) | 1.3 | $82M | -6% | 876k | 93.75 | |
| Dex (DXCM) | 1.2 | $77M | 150k | 511.60 | ||
| Ikena Oncology Nonvoting | 1.2 | $73M | 12M | 6.10 | ||
| Thermo Fisher Scientific (TMO) | 1.2 | $71M | +27% | 121k | 590.65 | |
| Natera Call Option (NTRA) | 1.2 | $71M | +23% | 1.7M | 40.68 | |
| Si-bone (SIBN) | 1.2 | $71M | +36% | 3.1M | 22.60 | |
| Crinetics Pharmaceuticals In (CRNX) | 1.1 | $70M | 3.2M | 21.95 | ||
| Prelude Therapeutics (PRLD) | 1.1 | $69M | 10M | 6.90 | ||
| Sierra Oncology Com New (SRRA) | 1.0 | $63M | +32% | 2.0M | 32.05 | |
| Global Blood Therapeutics In (GBT) | 0.9 | $56M | NEW | 1.6M | 34.64 | |
| Turning Point Therapeutics I (TPTX) | 0.9 | $54M | -4% | 2.0M | 26.85 | |
| Tenet Healthcare Corp Com New (THC) | 0.9 | $54M | +110% | 628k | 85.96 | |
| Argenx Se Sponsored Adr (ARGX) | 0.9 | $54M | NEW | 170k | 315.31 | |
| Xtant Med Hldgs Com New (XTNT) | 0.8 | $50M | 73M | 0.68 | ||
| Repare Therapeutics Ord (RPTX) | 0.8 | $47M | 3.3M | 14.24 | ||
| Meiragtx Holdings (MGTX) | 0.7 | $46M | -11% | 3.3M | 13.85 | |
| Kinnate Biopharma (KNTE) | 0.7 | $46M | +5% | 4.0M | 11.26 | |
| Evolent Health Cl A (EVH) | 0.7 | $45M | +49% | 1.4M | 32.30 | |
| Abcellera Biologics (ABCL) | 0.7 | $41M | 4.2M | 9.75 | ||
| Janux Therapeutics (JANX) | 0.7 | $41M | 2.8M | 14.34 | ||
| Nanostring Technologies (NSTG) | 0.7 | $40M | +43% | 1.2M | 34.75 | |
| Syndax Pharmaceuticals (SNDX) | 0.6 | $38M | +8% | 2.2M | 17.38 | |
| Alpine Immune Sciences (ALPN) | 0.6 | $37M | 4.1M | 8.97 | ||
| Vaxcyte (PCVX) | 0.6 | $37M | +38% | 1.5M | 24.15 | |
| Tela Bio (TELA) | 0.6 | $35M | 3.0M | 11.63 | ||
| Neuropace (NPCE) | 0.5 | $33M | 4.0M | 8.21 | ||
| Theravance Biopharma (TBPH) | 0.5 | $31M | -45% | 3.3M | 9.56 | |
| Silverback Therapeutics (SBTX) | 0.5 | $31M | 8.7M | 3.51 | ||
| Compass Therapeutics (CMPX) | 0.5 | $30M | 22M | 1.37 | ||
| Verona Pharma Sponsored Ads (VRNA) | 0.5 | $28M | 5.7M | 4.99 | ||
| Scpharmaceuticals (SCPH) | 0.4 | $27M | 4.8M | 5.68 | ||
| Aclaris Therapeutics (ACRS) | 0.4 | $27M | +60% | 1.6M | 17.24 | |
| Gh Research Ordinary Shares (GHRS) | 0.4 | $26M | 1.4M | 18.29 | ||
| Vectivbio Hldg Ord Shs (VECT) | 0.4 | $25M | +2% | 5.3M | 4.71 | |
| Fusion Pharmaceuticals (FUSN) | 0.4 | $25M | 3.2M | 7.77 | ||
| Biogen Idec (BIIB) | 0.4 | $25M | -48% | 118k | 210.60 | |
| Chinook Therapeutics (KDNY) | 0.4 | $23M | 1.4M | 16.36 | ||
| Adagio Therapeutics (ADGI) | 0.4 | $23M | 5.1M | 4.56 | ||
| Passage Bio (PASG) | 0.4 | $23M | +5% | 7.3M | 3.10 | |
| Xenon Pharmaceuticals (XENE) | 0.3 | $21M | +8% | 686k | 30.57 | |
| Jounce Therapeutics (JNCE) | 0.3 | $19M | 2.9M | 6.79 | ||
| Mereo Biopharma Group Ads (MREO) | 0.3 | $19M | 17M | 1.12 | ||
| Mersana Therapeutics (MRSN) | 0.3 | $19M | +65% | 4.8M | 3.99 | |
| Gracell Biotechnologies Sponsored Ads (GRCL) | 0.3 | $18M | 7.9M | 2.33 | ||
| Ikena Oncology (IKNA) | 0.3 | $18M | 2.9M | 6.10 | ||
| Ventyx Biosciences (VTYX) | 0.3 | $18M | 1.3M | 13.57 | ||
| Rxsight (RXST) | 0.3 | $17M | 1.4M | 12.38 | ||
| Gilead Sciences (GILD) | 0.3 | $17M | 288k | 59.45 | ||
| Uniqure Nv SHS (QURE) | 0.3 | $17M | +56% | 919k | 18.07 | |
| Milestone Pharmaceuticals (MIST) | 0.3 | $17M | 2.6M | 6.42 | ||
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $17M | NEW | 228k | 72.62 | |
| Vistagen Therapeutics Com New (VTGN) | 0.3 | $16M | 13M | 1.24 | ||
| Illumina (ILMN) | 0.3 | $16M | 45k | 349.40 | ||
| Harpoon Therapeutics (HARP) | 0.2 | $15M | +4% | 3.0M | 4.97 | |
| Decibel Therapeutics (DBTX) | 0.2 | $15M | 4.9M | 3.04 | ||
| Singular Genomics Systems In (OMIC) | 0.2 | $15M | +9% | 2.3M | 6.31 | |
| Synlogic (SYBX) | 0.2 | $15M | 6.0M | 2.40 | ||
| Bridgebio Pharma Note 2.250% 2/0 (Principal) | 0.2 | $14M | NEW | 30M | 0.48 | |
| Erasca (ERAS) | 0.2 | $14M | 1.7M | 8.60 | ||
| Celldex Therapeutics Com New (CLDX) | 0.2 | $14M | 406k | 34.06 | ||
| Amgen (AMGN) | 0.2 | $14M | 57k | 241.82 | ||
| 89bio (ETNB) | 0.2 | $14M | 3.7M | 3.77 | ||
| Burning Rock Biotech Sponsored Ads (BNR) | 0.2 | $14M | 1.5M | 9.29 | ||
| Nextcure (NXTC) | 0.2 | $13M | 2.7M | 4.86 | ||
| Galapagos Nv Spon Adr (GLPG) | 0.2 | $13M | -70% | 208k | 62.02 | |
| Danaher Corporation 5% Conv Pfd B (Principal) (DHR.PB) | 0.2 | $13M | -19% | 8.0k | 1579.30 | |
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.2 | $12M | 2.6M | 4.80 | ||
| Bridgebio Pharma Note 2.500% 3/1 (Principal) | 0.2 | $12M | NEW | 20M | 0.60 | |
| Corvus Pharmaceuticals (CRVS) | 0.2 | $11M | 6.9M | 1.64 | ||
| Signify Health Cl A Com (SGFY) | 0.2 | $11M | NEW | 621k | 18.15 | |
| Terns Pharmaceuticals (TERN) | 0.2 | $11M | 3.8M | 2.97 | ||
| Oric Pharmaceuticals (ORIC) | 0.2 | $11M | -10% | 2.1M | 5.34 | |
| Pulmonx Corp (LUNG) | 0.2 | $11M | 435k | 24.81 | ||
| Alx Oncology Hldgs (ALXO) | 0.2 | $11M | +199% | 622k | 16.90 | |
| Bellus Health Com New (BLU) | 0.2 | $10M | 1.5M | 6.92 | ||
| Spdr Ser Tr S&p Biotech (XBI) | 0.2 | $10M | -88% | 112k | 89.88 | |
| Aerovate Therapeutics (AVTE) | 0.2 | $9.3M | -4% | 510k | 18.33 | |
| Galecto (GLTO) | 0.1 | $9.0M | 4.1M | 2.20 | ||
| Cybin Ord (CYBN) | 0.1 | $8.6M | 11M | 0.82 | ||
| Imara (IMRA) | 0.1 | $8.2M | 4.4M | 1.88 | ||
| Gemini Therapeutics (GMTX) | 0.1 | $8.1M | 5.8M | 1.39 | ||
| Graphite Bio (GRPH) | 0.1 | $8.0M | 1.6M | 5.10 | ||
| Rapt Therapeutics (RAPT) | 0.1 | $7.9M | +66% | 361k | 21.99 | |
| Sonendo (SONX) | 0.1 | $7.9M | 2.0M | 4.01 | ||
| Cullinan Oncology (CGEM) | 0.1 | $7.0M | -16% | 671k | 10.47 | |
| Aeglea Biotherapeutics (AGLE) | 0.1 | $6.8M | 3.0M | 2.30 | ||
| Magenta Therapeutics (MGTA) | 0.1 | $6.5M | 2.3M | 2.90 | ||
| 9 Meters Biopharma (NMTR) | 0.1 | $6.2M | 10M | 0.60 | ||
| Nanostring Technologies Note 2.625% 3/0 (Principal) | 0.1 | $6.1M | 6.0M | 1.01 | ||
| Albireo Pharma (ALBO) | 0.1 | $5.8M | NEW | 194k | 29.83 | |
| Logicbio Therapeutics (LOGC) | 0.1 | $5.8M | 8.5M | 0.68 | ||
| Cytomx Therapeutics (CTMX) | 0.1 | $5.7M | -33% | 2.1M | 2.67 | |
| Chardan Healthcare Acqu- Ord (PHGE) | 0.1 | $5.4M | 2.8M | 1.93 | ||
| Oncocyte (OCX) | 0.1 | $5.2M | 3.5M | 1.49 | ||
| Graybug Vision Com Shs (GRAY) | 0.1 | $5.1M | 4.2M | 1.23 | ||
| Vor Biopharma (VOR) | 0.1 | $5.0M | 833k | 6.04 | ||
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $4.7M | 1.6M | 2.94 | ||
| Protara Therapeutics Com Stk (TARA) | 0.1 | $4.2M | 831k | 5.11 | ||
| Immunocore Hldgs Ads (IMCR) | 0.1 | $3.8M | NEW | 128k | 29.90 | |
| Acutus Medical (AFIB) | 0.1 | $3.7M | 2.6M | 1.39 | ||
| Sarepta Therapeutics (SRPT) | 0.0 | $3.1M | -33% | 39k | 78.11 | |
| Vigil Neuroscience | 0.0 | $2.9M | NEW | 411k | 7.03 | |
| Talaris Therapeutics (TALS) | 0.0 | $2.4M | 247k | 9.84 | ||
| X4 Pharmaceuticals (XFOR) | 0.0 | $2.4M | 1.4M | 1.75 | ||
| Sight Sciences (SGHT) | 0.0 | $2.3M | 200k | 11.56 | ||
| I Mab Sponsored Ads (IMAB) | 0.0 | $1.8M | 111k | 16.24 | ||
| Exscientia Ads (EXAI) | 0.0 | $1.8M | 125k | 14.40 | ||
| Aslan Pharmaceuticals Ads (ASLN) | 0.0 | $1.7M | 1.9M | 0.90 | ||
| Aptinyx (APTX) | 0.0 | $1.2M | -28% | 539k | 2.27 | |
| Cabaletta Bio (CABA) | 0.0 | $1.2M | +90% | 578k | 2.03 | |
| Field Trip Health Ord (FTRP) | 0.0 | $762k | -62% | 577k | 1.32 | |
| Longboard Pharmaceuticals In (LBPH) | 0.0 | $606k | 114k | 5.34 | ||
| Mirum Pharmaceuticals (MIRM) | 0.0 | $595k | NEW | 27k | 22.04 | |
| Pyxis Oncology Common Stock (PYXS) | 0.0 | $580k | 144k | 4.04 | ||
| Landos Biopharma (LABP) | 0.0 | $418k | 283k | 1.48 | ||
| Owlet *w Exp 09/14/202 (OWLT.WS) | 0.0 | $170k | 221k | 0.77 | ||
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022
- Orbimed Advisors 2021 Q3 filed Nov. 15, 2021
- Orbimed Advisors 2021 Q2 filed Aug. 16, 2021
- Orbimed Advisors 2021 Q1 filed May 17, 2021
- Orbimed Advisors 2020 Q4 filed Feb. 16, 2021
- Orbimed Advisors 2020 Q3 filed Nov. 16, 2020
- Orbimed Advisors 2020 Q2 filed Aug. 14, 2020
- Orbimed Advisors 2020 Q1 filed May 15, 2020
- Orbimed Advisors 2019 Q4 filed Feb. 14, 2020
- Orbimed Advisors 2019 Q3 filed Nov. 14, 2019
- Orbimed Advisors 2019 Q2 filed Aug. 14, 2019
- Orbimed Advisors 2019 Q1 filed May 15, 2019
- Orbimed Advisors 2018 Q4 filed Feb. 14, 2019
- Orbimed Advisors 2018 Q3 filed Nov. 14, 2018
- Orbimed Advisors 2018 Q2 filed Aug. 14, 2018